Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2023) 90 EP529 | DOI: 10.1530/endoabs.90.EP529

ECE2023 Eposter Presentations Diabetes, Obesity, Metabolism and Nutrition (355 abstracts)

The efficacy of regimens for sodium-glucose countertranspoter 2 inhibitor (Emaglyf) with metformin and DPP-4 inhibitor (Januvia) in patients with DM 2 and stage 1-3 chronic kidney disease

Mokhira Teshabekova


Republican Specialized Scientific Practical Medical Center of Endocrinology of Public Health Ministry named by acad. Ya.Kh. Turakulov, Department of Diabetic Nephropathy, Tashkent, Uzbekistan.


Aim of the study: To study the effectiveness of combination therapy of sodium-glucose countertranspoter 2 inhibitor -SGLT-2 – (Emaglyf) with metformin and DPP-4 inhibitor (Januvia) in patients with stage 1–3 chronic kidney disease associated with DM 2.

Material and research methods: A total of 40 patients with type 2 diabetes and CKD grades 1–4 were selected. To study the effect of various schemes of nephroprotective therapy on the functional state of the kidneys in DM 2, patients were divided into 2 therapeutic groups:

Group 1 consisted of 20 patients with DM 2 and CKD 1–3 tbsp. receivingSGLT-2 (emoglyph) + metformin Group 2 consisted of 20 patients with DM 2 and CKD 1–3 tbsp. receivingSGLT-2 (Emoglyph) + DPP 4 (Januvia). In the work, general clinical, clinical and biochemical (AL, AST, bilirubin, PTI, urea, creatinine, GFR, C-reactive protein, etc.), hormonal (insulin, C-peptide), immunological (uromodulin) methods of blood tests, as well as instrumental methods of examination – ultrasound of internal organs, Ultrasound and dopplerography of renal vessels, as well as statistical methods. We also evaluated the results of ECG in 12 conventional leads and echocardiography (EchoCG) (dimensions of the chambers of the heart, the thickness of its walls and myocardial contractility). The control group consisted of 20 healthy individuals.

Research results: The initial data of carbohydrate metabolism indicated its decompensation in the studied groups. There were no significant differences between the Doppler values of the renal arteries in the groups. At the same time, the indicators significantly differed from those of the control group.

Conclusions: 1) After 6 months of therapy, the indicators of carbohydrate metabolism reached normalization in both groups, while the best results were observed when using the SGLT-2+ DPP4 regimen

2) After 6 months of treatment, significant differences were found between the Doppler values of the renal arteries in the groups, namely, when using the SGLT-2+ DPP4 scheme

Volume 90

25th European Congress of Endocrinology

Istanbul, Turkey
13 May 2023 - 16 May 2023

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.

Authors